tiprankstipranks
Amgen Inc (MX:AMGN)
NASDAQ:AMGN
Mexico Market
AMGN
Amgen
RESEARCH TOOLSreports

Amgen (AMGN) Stock Forecast & Price Target

― Followers
See the Price Targets and Ratings of:

AMGN Analyst Ratings

Moderate Buy
24Ratings
Moderate Buy
10 Buy
13 Hold
1 Sell
Based on 24 analysts giving stock ratings to
Amgen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AMGN Stock 12 Month Forecast

Average Price Target

$6,267.56
Based on 24 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is $6,267.56 with a high forecast of $7,476.28 and a low forecast of $5,252.65. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5185":"$5,185","5758":"$5,758","6331":"$6,331","6904":"$6,904","7477":"$7,477"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7476.27552119,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6267.561370212035,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5252.652591,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.25K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5185,5758,6331,6904,7477],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6250.39,6344.688886245385,6438.987772490769,6533.286658736154,6627.585544981539,6721.884431226923,6816.183317472308,6910.482203717693,7004.781089963077,7099.079976208462,7193.3788624538465,7287.6777486992305,7381.976634944615,{"y":7476.27552119,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6250.39,6251.710874631695,6253.03174926339,6254.352623895085,6255.67349852678,6256.994373158475,6258.31524779017,6259.636122421865,6260.95699705356,6262.277871685255,6263.59874631695,6264.919620948645,6266.24049558034,{"y":6267.561370212035,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6250.39,6173.6409685384615,6096.891937076924,6020.142905615385,5943.393874153847,5866.644842692308,5789.895811230769,5713.146779769231,5636.397748307692,5559.648716846154,5482.899685384616,5406.150653923077,5329.401622461539,{"y":5252.652591,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5290.509,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5501.158,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5230.256,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5356.017,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5186.222,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6109.182,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5849.008,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6011.617,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6666.091,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6272.159,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6013.176,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5858,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6250.39,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$7,476Average Price Target$6,268Lowest Price Target$5,253
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on MX:AMGN
Courtney Breen
Bernstein
Bernstein
$5,865.46
Hold
―
Reiterated
07/22/26
Bernstein Reaffirms Their Hold Rating on Amgen (AMGN)
Citi Analyst forecast on MX:AMGN
Geoff Meacham
Citi
Citi
$6,040.55
Hold
―
Reiterated
07/15/26
Citi Sticks to Its Hold Rating for Amgen (AMGN)
Wells Fargo Analyst forecast on MX:AMGN
Mohit Bansal
Wells Fargo
Wells Fargo
$6,828.45
Hold
―
Reiterated
07/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Denali Therapeutics (NASDAQ: DNLI) and Amgen (NASDAQ: AMGN)
Bank of America Securities Analyst forecast on MX:AMGN
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$5,375.21→$5,462.76
Sell
―
Reiterated
07/13/26
Analyst Maintains Sell on Amgen as Shares Trade Above Newly Raised $312 Price Target and Near-Term Growth Remains Limited
BMO Capital Analyst forecast on MX:AMGN
Evan Seigerman
BMO Capital
BMO Capital
$7,003.54
Buy
―
Reiterated
07/13/26
BMO Capital Sticks to Their Buy Rating for Amgen (AMGN)
UBS Analyst forecast on MX:AMGN
Michael Yee
UBS
UBS
$7,003.54→$7,353.71
Buy
―
Assigned
07/13/26
Amgen price target raised to $420 from $400 at UBSAmgen price target raised to $420 from $400 at UBS
Guggenheim Analyst forecast on MX:AMGN
Vamil Divan
Guggenheim
Guggenheim
$5,953.01→$6,005.53
Hold
―
Reiterated
07/10/26
Amgen price target raised to $343 from $340 at GuggenheimAmgen price target raised to $343 from $340 at Guggenheim
Morgan Stanley Analyst forecast on MX:AMGN
Terence Flynn
Morgan Stanley
Morgan Stanley
$5,953.01→$5,830.44
Hold
―
Reiterated
07/08/26
Amgen price target lowered to $333 from $340 at Morgan StanleyAmgen price target lowered to $333 from $340 at Morgan Stanley
Truist Financial Analyst forecast on MX:AMGN
Gregory Renza
Truist Financial
Truist Financial
$5,725.39→$5,953.01
Hold
―
Reiterated
07/07/26
Amgen price target raised to $340 from $327 at TruistAmgen price target raised to $340 from $327 at Truist
RBC Capital Analyst forecast on MX:AMGN
Luca Issi
RBC Capital
RBC Capital
$6,478.27
Buy
―
Reiterated
07/07/26
Amgen (AMGN) Receives a Buy from RBC Capital
Piper Sandler Analyst forecast on MX:AMGN
David Amsellem
Piper Sandler
Piper Sandler
$7,476.28
Buy
―
Reiterated
06/29/26
Analysts' Top Healthcare Picks: Amgen (AMGN), BridgeBio Pharma (BBIO)
Mizuho Securities Analyst forecast on MX:AMGN
Salim Syed
Mizuho Securities
Mizuho Securities
$5,305.18
Hold
―
Reiterated
06/21/26
Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (NYSE MKT: PTHS), Neumora Therapeutics, Inc. (NASDAQ: NMRA) and Amgen (NASDAQ: AMGN)
Goldman Sachs Analyst forecast on MX:AMGN
Salveen Richter
Goldman Sachs
Goldman Sachs
$7,441.26→$6,810.94
Buy
―
Reiterated
06/05/26
Amgen price target lowered to $389 from $425 at Goldman SachsAmgen price target lowered to $389 from $425 at Goldman Sachs
TD Cowen Analyst forecast on MX:AMGN
Yaron Werber
TD Cowen
TD Cowen
$7,353.71→$5,713.31
Buy
―
Reiterated
05/18/26
Analysts Offer Insights on Healthcare Companies: Novartis (NYSE: NVS), Amgen (NASDAQ: AMGN) and Bristol-Myers Squibb (NYSE: BMY)
Freedom Capital Markets Analyst forecast on MX:AMGN
Ilya Zubkov
Freedom Capital Markets
Freedom Capital Markets
$6,565.82
Buy
―
Upgraded
05/07/26
Amgen upgraded to Buy from Hold at Freedom BrokerAmgen upgraded to Buy from Hold at Freedom Broker
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on MX:AMGN
Courtney Breen
Bernstein
Bernstein
$5,865.46
Hold
―
Reiterated
07/22/26
Bernstein Reaffirms Their Hold Rating on Amgen (AMGN)
Citi Analyst forecast on MX:AMGN
Geoff Meacham
Citi
Citi
$6,040.55
Hold
―
Reiterated
07/15/26
Citi Sticks to Its Hold Rating for Amgen (AMGN)
Wells Fargo Analyst forecast on MX:AMGN
Mohit Bansal
Wells Fargo
Wells Fargo
$6,828.45
Hold
―
Reiterated
07/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Denali Therapeutics (NASDAQ: DNLI) and Amgen (NASDAQ: AMGN)
Bank of America Securities Analyst forecast on MX:AMGN
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$5,375.21→$5,462.76
Sell
―
Reiterated
07/13/26
Analyst Maintains Sell on Amgen as Shares Trade Above Newly Raised $312 Price Target and Near-Term Growth Remains Limited
BMO Capital Analyst forecast on MX:AMGN
Evan Seigerman
BMO Capital
BMO Capital
$7,003.54
Buy
―
Reiterated
07/13/26
BMO Capital Sticks to Their Buy Rating for Amgen (AMGN)
UBS Analyst forecast on MX:AMGN
Michael Yee
UBS
UBS
$7,003.54→$7,353.71
Buy
―
Assigned
07/13/26
Amgen price target raised to $420 from $400 at UBSAmgen price target raised to $420 from $400 at UBS
Guggenheim Analyst forecast on MX:AMGN
Vamil Divan
Guggenheim
Guggenheim
$5,953.01→$6,005.53
Hold
―
Reiterated
07/10/26
Amgen price target raised to $343 from $340 at GuggenheimAmgen price target raised to $343 from $340 at Guggenheim
Morgan Stanley Analyst forecast on MX:AMGN
Terence Flynn
Morgan Stanley
Morgan Stanley
$5,953.01→$5,830.44
Hold
―
Reiterated
07/08/26
Amgen price target lowered to $333 from $340 at Morgan StanleyAmgen price target lowered to $333 from $340 at Morgan Stanley
Truist Financial Analyst forecast on MX:AMGN
Gregory Renza
Truist Financial
Truist Financial
$5,725.39→$5,953.01
Hold
―
Reiterated
07/07/26
Amgen price target raised to $340 from $327 at TruistAmgen price target raised to $340 from $327 at Truist
RBC Capital Analyst forecast on MX:AMGN
Luca Issi
RBC Capital
RBC Capital
$6,478.27
Buy
―
Reiterated
07/07/26
Amgen (AMGN) Receives a Buy from RBC Capital
Piper Sandler Analyst forecast on MX:AMGN
David Amsellem
Piper Sandler
Piper Sandler
$7,476.28
Buy
―
Reiterated
06/29/26
Analysts' Top Healthcare Picks: Amgen (AMGN), BridgeBio Pharma (BBIO)
Mizuho Securities Analyst forecast on MX:AMGN
Salim Syed
Mizuho Securities
Mizuho Securities
$5,305.18
Hold
―
Reiterated
06/21/26
Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (NYSE MKT: PTHS), Neumora Therapeutics, Inc. (NASDAQ: NMRA) and Amgen (NASDAQ: AMGN)
Goldman Sachs Analyst forecast on MX:AMGN
Salveen Richter
Goldman Sachs
Goldman Sachs
$7,441.26→$6,810.94
Buy
―
Reiterated
06/05/26
Amgen price target lowered to $389 from $425 at Goldman SachsAmgen price target lowered to $389 from $425 at Goldman Sachs
TD Cowen Analyst forecast on MX:AMGN
Yaron Werber
TD Cowen
TD Cowen
$7,353.71→$5,713.31
Buy
―
Reiterated
05/18/26
Analysts Offer Insights on Healthcare Companies: Novartis (NYSE: NVS), Amgen (NASDAQ: AMGN) and Bristol-Myers Squibb (NYSE: BMY)
Freedom Capital Markets Analyst forecast on MX:AMGN
Ilya Zubkov
Freedom Capital Markets
Freedom Capital Markets
$6,565.82
Buy
―
Upgraded
05/07/26
Amgen upgraded to Buy from Hold at Freedom BrokerAmgen upgraded to Buy from Hold at Freedom Broker
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
GKOSGlaukos
ARDXArdelyx
STOKStoke Therapeutics
MIRMMirum Pharmaceuticals
CSTLCastle Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amgen

3 Months
David AmsellemPiper Sandler
Success Rate
13/18 ratings generated profit
72%
Average Return
+5.58%
Copying David Amsellem's trades and holding each position for 3 Months would result in 72.22% of your transactions generating a profit, with an average return of +5.58% per trade.
1 Year
David AmsellemPiper Sandler
Success Rate
17/18 ratings generated profit
94%
Average Return
+19.09%
Copying David Amsellem's trades and holding each position for 1 Year would result in 94.44% of your transactions generating a profit, with an average return of +19.09% per trade.
2 Years
Salveen RichterGoldman Sachs
Success Rate
18/18 ratings generated profit
100%
Average Return
+25.80%
Copying Salveen Richter's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +25.80% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AMGN Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
27
25
25
26
18
Hold
20
25
27
27
21
Sell
2
1
2
2
2
Strong Sell
0
0
0
0
0
total
49
51
54
55
41
In the current month, AMGN has received 18 Buy Ratings, 21 Hold Ratings, and 2 Sell Ratings. AMGN average Analyst price target in the past 3 months is 6,267.56.
Each month's total comprises the sum of three months' worth of ratings.

AMGN Financial Forecast

AMGN Earnings Forecast

Next quarter’s earnings estimate for AMGN is $98.33 with a range of $87.37 to $109.96. The previous quarter’s EPS was $90.17. AMGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year AMGN has Performed in-line its overall industry.
Next quarter’s earnings estimate for AMGN is $98.33 with a range of $87.37 to $109.96. The previous quarter’s EPS was $90.17. AMGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year AMGN has Performed in-line its overall industry.

AMGN Sales Forecast

Next quarter’s sales forecast for AMGN is $165.17B with a range of $161.82B to $168.54B. The previous quarter’s sales results were $151.52B. AMGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year AMGN has Performed in-line its overall industry.
Next quarter’s sales forecast for AMGN is $165.17B with a range of $161.82B to $168.54B. The previous quarter’s sales results were $151.52B. AMGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year AMGN has Performed in-line its overall industry.

AMGN Stock Forecast FAQ

What is MX:AMGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Amgen Inc’s 12-month average price target is 6,267.56.
    What is MX:AMGN’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for MX:AMGN, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Amgen Inc a Buy, Sell or Hold?
        Amgen Inc has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 13 hold ratings and 1 sell ratings.
          What is Amgen Inc’s share price target?
          The average share price target for Amgen Inc is 6,267.56. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $7,476.28 ,and the lowest forecast is $5,252.65. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Amgen Inc?
            Amgen Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 24 Wall Streets Analysts.
              How can I buy shares of Amgen Inc?
              To buy shares of MX:AMGN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.